-
Mustang Bio, Mayo Clinic Join Forces On New CAR T Tech In Tumor Settings
Friday, August 13, 2021 - 10:03am | 248Read More...Mustang Bio Inc (NASDAQ: MBIO) executed an exclusive license agreement with Mayo Clinic for a new approach to administering chimeric antigen receptor engineered T cell (CAR T) therapies and potentially be used as an off-the-shelf therapy. The technology uses a two-step...
-
FDA Oncology Adcomm Votes To Keep Conditional Approval For Roche's Tecentriq In Place For Now
Wednesday, April 28, 2021 - 9:16am | 365Read More...The FDA kicked off a three-day meet to reexamine the accelerated approvals of immuno-oncology drugs with confirmatory trials that have not met their primary endpoint(s) and have yet to gain regular approvals. FDA’s Oncologic Drugs Advisory Committee (ODAC) started the meet with Roche...
-
Aptorum Shares Are Trading Higher On Immunomodulators Agreement For Autoimmune, Oncology Indications
Thursday, April 22, 2021 - 9:04am | 195Read More...Aptorum Group Ltd (NASDAQ: APM) has entered into a material transfer and option agreement with Yale University to evaluate a group of preclinical stage novel immunomodulators. Aptorum also obtained an exclusive option to in-license the novel immunomodulators and related...
-
BridgeBio Locks $2B Infigratinib Global Partnership For Oncology Indications
Wednesday, March 31, 2021 - 11:46am | 370Read More...At the start of March, BridgeBio Pharma Inc (NASDAQ: BBIO) won approval for its first drug, fosdenopterin, for sporadic cases of molybdenum cofactor deficiency type A. In the middle of March, it announced positive proof-of-concept data for encaleret for Autosomal Dominant...
-
Novartis Beefs Up Radioligand Portfolio With iTheranostics Deal
Tuesday, March 30, 2021 - 12:51pm | 244Read More...Just a week after acing Phase 3 study evaluating radioligand therapy in prostate cancer, Novartis AG (NYSE: NVS) is licensing the rights to develop and commercialize treatments based on a library of radioligand compounds from iTheranostics, a subsidiary of Sofie...
-
Lantheus Buys Rights To Fibroblast Activation Protein Targeting Imaging Biomarker
Tuesday, March 30, 2021 - 12:44pm | 205Read More...Lantheus Holdings Inc (NASDAQ: LNTH) has acquired the exclusive worldwide rights to develop, manufacture and commercialize NTI-1309, a PET oncology imaging agent from Noria Therapeutics Inc. NTI-1309 targets fibroblast activation protein (FAP), a target with potential...
-
Takeda To Expand Immuno-Oncology Portfolio With Maverick Therapeutics Acquisition
Tuesday, March 9, 2021 - 10:27am | 233Read More...Takeda Pharmaceutical Co Ltd (NYSE: TAK) has exercised the option to acquire Maverick Therapeutics, following an agreement signed in 2017, in which Takeda received an equity stake and an exclusive right to purchase Maverick after five years. Under the agreement, Takeda will...
-
Lantern Pharma CEO Discusses The Addition Of Its New ADC Program And The Resurgence Of ADC Therapy For Cancer Treatment
Monday, February 22, 2021 - 9:52am | 1353Read More...The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharma company, debuted as a public company on June 15, 2020. In merely the seven...
-
Molecular Templates Shares Jump On Research Pact With Bristol-Myers In Cancer Settings
Thursday, February 11, 2021 - 10:13am | 249Read More...Molecular Templates Inc (NASDAQ: MTEM) has entered into a worldwide strategic research collaboration with Bristol-Myers Squibb Co (NYSE: BMY) to discover new molecules utilizing MTEM's engineered toxin body (ETB) platform for specific oncology targets. Under...
-
Veracyte Scoops Up Decipher Biosciences For $600M, Reports Fourth Quarter Interim Results
Wednesday, February 3, 2021 - 9:13am | 286Read More...Veracyte Inc (NASDAQ: VCYT) has agreed to acquire Decipher Biosciences, a precision oncology company focused on urologic cancers, further solidifying Veracyte's position in the genomic cancer diagnostics market. Veracyte will pay $600 million in total consideration,...
-
10 Biopharmaceutical Companies Trying To Cure Cancer
Saturday, August 24, 2019 - 1:46pm | 1041Read More...Cancer. Research shows nearly every sixth death in the world is due to the disease, making it the second leading cause of death behind cardiovascular diseases. The global pharmaceutical industry is estimated at an astounding $1.11 trillion in size. Every year, billions are spent on the...
-
Turning Point Therapeutics IPO: What You Need To Know
Wednesday, April 17, 2019 - 11:01am | 323Read More...When Turning Point Therapeutics hits the markets Wednesday, it wants to pivot your portfolio toward the rich field of oncology. The IPO Turning Point has priced 9.25 million shares at $18 per share on the Nasdaq under ticker "TPTX." The offering represents 30.2 percent of outstanding...
-
Eli Lilly Agrees To Buy Loxo For $8B In Bid To Expand Oncology Franchise
Monday, January 7, 2019 - 10:00am | 478Read More...Achieving excellence in oncology franchises is driving large-cap companies to make astute buys of relatively smaller-sized companies with breakthrough pipeline assets in the field. Eli Lilly And Co (NYSE: LLY) has become the latest company to have made a move in this direction. What Happened Less...
-
G1 Therapeutics Investors Recoil, Analysts Bullish In Wake Of Trilaciclib Results
Thursday, December 20, 2018 - 11:28am | 433Read More...G1 Therapeutics Inc (NASDAQ: GTHX) reported positive top-line results Wednesday for its Phase 2 trilaciclib trial in small cell lung cancer. What Happened The candidate met primary endpoints in reducing the occurrence and duration of severe neutropenia. Compared to the placebo, it also allowed...
-
Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate
Tuesday, December 11, 2018 - 1:42pm | 508Read More...Clovis Oncology Inc (NASDAQ: CLVS) has emerged as a strong takeover candidate following GlaxoSmithKline plc (NYSE: GSK)'s proposed acquisition of TESARO Inc (NASDAQ: TSRO), according to Gabelli Research. The Analyst Analyst Jing He named Clovis as his top pick in 2019. The analyst...
